1581P Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors (ICIs): Pooled analysis of individual cases from multiple institutions and literature
نویسندگان
چکیده
Immune checkpoint inhibitors (ICIs) have revolutionized the management of multiple tumors, due to improved efficacy, quality life and safety. While most immune-related adverse events (irAEs) are mild easily managed, in rare cases such may be life-threatening, especially those affecting neuromuscular cardiac system. The neuromuscular/cardiac irAEs is not clear lack consistent data. Therefore, we performed a pooled analysis collected from selected Italian centers individual data published case reports series, order improve our understanding these irAEs. We retrospective patients treated 6 with ICIs (PD-1 or PD-L1 and/or CTLA-4 inhibitor) for any solid tumor who experienced cardiovascular toxicity. Then, increase caseload, search series tumor. Our includes institutions (n=18) identified systematic literature (n=112), total 130 patients. Among patients, 44 had complete resolution their irAEs, 21 there was clinical improvement sequelae, 52 died as result Factors significantly associated worse outcomes were earlier irAE onset, within first 2 cycles ICI (Fisher P< 0.0001), manifestation both myositis myocarditis if compared developed only (Chi-square P= 0.0051), increased peak troponin value ((Mann-Whitney 0.0346) development arrythmia 0.0051). To knowledge, this widest collection myocarditis/myositis. Early concurrent myocarditis, occurrence arrythmias should encourage an aggressive immunomodulatory treatment.
منابع مشابه
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
متن کامل
Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials
Telmisartan is indicated for the prevention of cardiovascular events in high-risk patients, based on comparable efficacy to the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET(®)) trial. However, tolerability must be considered when selecting treatments. This analysis compared the tolerabi...
متن کاملAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
BACKGROUND Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. S...
متن کاملsynthesis of sulfides from alcohols and thiols in solvent-freeconditions and deoxygenation of sulfoxides
کاتالیست یک سنتز جدید برای تیواترها توصیف شده است. واکنش الکل ها با آریل، هتروآریل و آلکیل تیو ل ها درحضور 1،3،5- تری آزو- 2،4،6- تری فسفرین-2،2،4،4،6،6 هگزاکلراید ((tapc به عنوان یک کاتالیست موُثر، بازده های خوب تا عالی از تیواترها را حاصل می کند. علاوه براین، واکنش تحت شرایط بدون فلز و بدون حلال پیش می رود، بنابراین یک مکمل جالب برای روش های شناخته شده سنتز تیواترها ارائه می دهد. یک مکانیسم ا...
15 صفحه اولProton Pump Inhibitors and the Risk of Adverse Cardiac Events
BACKGROUND Recent evidence suggests that proton pump inhibitors (PPIs) might be linked with adverse cardiac events, but a causal relationship is unproven. METHODS We applied the self-matched case series method to two studies using population-based health care data from Ontario, Canada between 1996 and 2008. The first included subjects aged 66 years or older hospitalized for acute myocardial i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2022
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2022.07.1674